https://doi.org/10.5217/ir.2024.00118 • Intest Res 2025;23(3):358-371

Supplementary Table 4. At 6-, 12-, 18-, and 24-Month Persistence of the Index Biologic in Patients with Crohn's Disease or Ulcerative Colitis by Hospital Admission Status on the Index Date

Index treatment	Status at index	6 mo persistence with ≥ 6 mo continuous observation		12 mo persistence with ≥ 12 mo continuous observation		18 mo persistence with ≥ 18 mo continuous observation		24 mo persistence with ≥ 24 mo continuous observation	
		No. (%)	Total	No. (%)	Total	No. (%)	Total	No. (%)	Total
Crohn's disease									
Adalimumab	Inpatient	108 (89.3)	121	94 (83.2)	113	82 (77.4)	106	67 (73.6)	91
	Outpatient	290 (92.7)	313	254 (85.2)	298	209 (80.7)	259	174 (77.3)	225
Infliximab	Inpatient	219 (95.6)	229	190 (90.5)	210	156 (86.2)	181	134 (83.8)	160
	Outpatient	150 (92.0)	163	131 (84.0)	156	104 (76.5)	136	81 (67.5)	120
Vedolizumab	Inpatient	5 (62.5)	8	2 (25.0)	8	1 (20.0)	5	0	3
	Outpatient	20 (83.3)	24	15 (62.5)	24	8 (50.0)	16	4 (36.4)	11
Ustekinumab	Inpatient	50 (92.6)	54	42 (91.3)	46	35 (87.5)	40	28 (80.0)	35
	Outpatient	128 (95.5)	134	115 (91.3)	126	85 (88.5)	96	58 (80.6)	72
Ulcerative colitis									
Adalimumab	Inpatient	72 (69.2)	104	57 (57.0)	100	39 (45.9)	85	30 (43.5)	69
	Outpatient	240 (67.6)	355	193 (57.8)	334	158 (52.3)	302	126 (49.6)	254
Infliximab	Inpatient	253 (73.3)	345	198 (61.1)	324	152 (54.9)	277	115 (48.1)	239
	Outpatient	214 (79.6)	269	165 (65.2)	253	123 (54.9)	224	101 (51.8)	195
Golimumab	Inpatient	28 (70.0)	40	18 (47.4)	38	15 (42.9)	35	10 (34.5)	29
	Outpatient	125 (74.9)	167	89 (56.7)	157	68 (51.1)	133	53 (44.9)	118
Vedolizumab	Inpatient	38 (66.7)	57	30 (55.6)	54	22 (55.0)	40	13 (52.0)	25
	Outpatient	230 (85.2)	270	177 (72.8)	243	123 (66.1)	186	82 (60.7)	135
Ustekinumab	Inpatient	18 (94.7)	19	15 (83.3)	18	8 (80.0)	10	5 (83.3)	6
	Outpatient	80 (95.2)	84	64 (84.2)	76	32 (82.1)	39	13 (72.2)	18
Tofacitinib	Inpatient	13 (68.4)	19	12 (63.2)	19	8 (61.5)	13	3 (60.0)	5
	Outpatient	81 (68.1)	119	65 (61.3)	106	39 (49.4)	79	31 (47.0)	66